StemCells, Inc.'s Phase II Pathway Study for Cervical Spinal Cord Injury Approved by Health Canada
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Cantor Fitzgerald Expects StemCells (STEM) to Present GA Data This Week; Reiterates Buy
June 22, 2015 7:03 AM EDTCantor Fitzgerald reiterates a Buy rating and $2.00 price target on StemCells (NASDAQ: STEM) ahead of GA data that is anticipated to be Presented this week. Analyst Caroline Corner expects positive results, based on interim data.
Corner commented, "We anticipate that data will be... More
StemCells (STEM) Receives Approval from Health Canada to Expand Pathway Study
June 18, 2015 8:06 AM EDTStemCells (NASDAQ: STEM) announced that Health Canada has authorized the Company to expand its Phase II clinical trial for chronic cervical spinal cord injury into Canada. The Pathway Study is designed to assess the efficacy of the Company's proprietary HuCNS-SC® platform technology (purified human... More
